Nixed Pfizer Inversion Casts Uncertainty On Similar Deals
Pfizer's scrapped plans for its record $160 billion corporate inversion with Irish drugmaker Allergan may be just one casualty of the U.S. Department of Treasury's latest rulemaking, but the thwarted deal...To view the full article, register now.
Already a subscriber? Click here to view full article